PUBLIC COMPANY
save$EVMNEvommune, Inc.
$EVMN6.0400+1.68%Palo Alto, CA, USupdated 12d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study of EVO756 in Adults With Migraine
- phase2Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
- phase2Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
- phase2Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
- phase2A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
- phase2Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
🐶 Hiring Signal
News
- Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gapEvommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures…biospace · 11d ago
- Evommune's lead drug fails in chronic hives, stock sinksEvommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin condit…endpoints · 4mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that